Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Good Things in Threes: Trius Therapeutics Files for IPO to Fund Phase 3 Clinical Trials, Marks San Diego’s Third IPO Filing
|
Bruce V. Bigelow |
11/09/09 |
San Diego
|
|
UK’s Enigma Diagnostics to Establish U.S. Headquarters in San Diego
|
Bruce V. Bigelow |
10/27/09 |
San Diego
|
|
Trius Approaches Next Stage in Drug Development, China Partnerships a Hot Topic at CalAsia, Lpath Headed to Critical Juncture, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/18/09 |
San Diego
|
|
Trius Looks to Cut a Deal, Gears Up For Final Stage of Trials with New Antibiotic
|
Luke Timmerman |
06/12/09 |
San Diego
|
|
Anadys Cuts Jobs, Obesity Drug Developers Show Intriguing Results, Trius Antibiotic Passes Key Test, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/11/09 |
San Diego
|
|
Trius, Developer of Antibiotic for Deadly MRSA Bacteria, Passes Key Test
|
Luke Timmerman |
06/08/09 |
San Diego
|
|
Moving Fast, Trius Therapeutics Assesses Capital Needs for Late-Stage Clinical Trials
|
Bruce V. Bigelow |
04/07/09 |
San Diego
|
|
Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections
|
Luke Timmerman |
03/30/09 |
Seattle
|
|
Vioguard CEO Larry Ranta Takes Germ-Zapping Keyboard Into Growing Hospital Market
|
Gregory T. Huang |
03/26/09 |
Seattle
|
|
Calixa Passes Key Safety Test in Clinical Trial of New Antibiotic
|
Luke Timmerman |
03/24/09 |
San Diego
|
|
Novophage Forming to Combat Antibiotic Resistance with Engineered Viruses
|
Ryan McBride |
03/05/09 |
Boston
|
|
Teva Takes Aim at Cubist Pharma’s Key Antibiotic Business
|
Ryan McBride |
02/10/09 |
Boston
|
|
Rib-X Raises $25M in Debt Financing, Reveals Final Results of Antibiotic Trial
|
Ryan McBride |
01/26/09 |
Boston
|
|
Cepheid, Maker of Test to Spot MRSA Staph Infections, Builds Growing Presence in Washington
|
Luke Timmerman |
12/22/08 |
Seattle
|
|
Targanta Faces New Challenges to Raise Cash After FDA Shoots Down the Firm’s Antibiotic
|
Ryan McBride |
12/10/08 |
Boston
|
|
Rib-X Reveals “Positive” Antibiotic Data
|
Ryan McBride |
12/08/08 |
Boston
|
|
Simple DNA Test Spots Deadly MRSA Bacteria; Adnavance Aims To Take It Mainstream
|
Luke Timmerman |
11/10/08 |
San Diego
|
|
Isis Spinoff Ibis Biosciences, Looking at DNA of Infectious Bugs, Aims to Identify What They Are, Faster
|
Luke Timmerman |
10/27/08 |
San Diego
|
|
Targanta Releases Antibiotic Data
|
Ryan McBride |
10/22/08 |
Boston
|
|
Trius Therapeutics Wins $28M Contract From NIH For Bioterror Antibiotics
|
Luke Timmerman |
10/22/08 |
San Diego
|
|
Trius Therapeutics, Developer of Antibiotic Against MRSA, Taking On Pfizer’s Zyvox
|
Luke Timmerman |
10/20/08 |
San Diego
|
|
Targanta Preps For FDA Advisory Panel on New Antibiotic
|
Luke Timmerman |
10/14/08 |
Boston
|
|
Targanta Aims to “Simplifi” Treatment of Deadly Bugs With Single-Shot Antibiotic
|
Luke Timmerman |
09/22/08 |
Boston
|
|
Targanta Antibiotic Shown Effective in Less-Frequent Dose
|
Luke Timmerman |
09/02/08 |
Boston
|
|
Navilyst Medical, Boston Scientific Spin-Off, Aiming to Tap Veins Without Causing Infections
|
Luke Timmerman |
08/05/08 |
Boston
|
|
Thermo Fisher MRSA Test Approved
|
Rebecca Zacks |
04/04/08 |
Boston
|
|
Nomir to Microbes: We’re Out to Get You
|
Rebecca Zacks |
11/01/07 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
